High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib

Published:2013-09 Issue:9 Volume:8 Page:e85-e86
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kim Young Hak,Ozasa Hiroaki,Nagai Hiroki,Sakamori Yuichi,Yoshida Hironori,Yagi Yoshitaka,Nakaoku Takashi,Mishima Michiaki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference4 articles.

1. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer;Kaneda;J Thorac Oncol,2013

2. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib;Costa;J Clin Oncol,2011

3. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib;Jackman;J Clin Oncol,2006

4. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer;Gandhi;J Thorac Oncol,2013

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current pharmacologic treatment of brain metastasis in non-small cell lung cancer;Clinical & Experimental Metastasis;2024-03-11

2. Does Crizotinib Auto-Inhibit CYP3A in vivo?;Pharmacology;2020

3. Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment;Frontiers in Oncology;2018-04-11

4. Treating ALK-positive non-small cell lung cancer;Annals of Translational Medicine;2018-04

5. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors;Human Molecular Genetics;2017-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3